Close
Close

Anti-C50H99NO8S T cell receptor (Vα14Vβ8.2), pCDTCR1 (TCR-YC0255)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-C50H99NO8S T cell receptor (TCR) is constructed for the engineering of T cell to target C50H99NO8S (N-[(2S,3S,4R)-1-(alpha-D-galactosyloxy)-3,4-dihydroxyoctadecan-2-yl]hexacosanethioamide) restricted by mouse CD1d. The T cells are genetically modified through transduction with a lentiviral vector expressing C50H99NO8S-specific T cell receptor.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • C50H99NO8S
  • Epitope
  • N-[(2S,3S,4R)-1-(alpha-D-galactosyloxy)-3,4-dihydroxyoctadecan-2-yl]hexacosanethioamide
  • Format
  • Non-Modified TCR
  • Allele
  • mouse CD1d
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • Vα14Vβ8.2
  • Host Species
  • Mouse

Target

  • Introduction
  • Natural killer T cells (NKT cells), unlike conventional T cells, specifically recognize self lipid– or foreign lipid–based antigens bound to the monomorphic MHC class I–like molecule CD1d. NKT cells have been linked to microbial immunity, autoimmunity, allergy and cancer and, accordingly, they represent an important immunotherapeutic target with immense clinical potential. Type I NKT cells express a semi-invariant TCR that has an invariant α-chain and a restricted TCRβ repertoire (α-chain variable region 24–α-chain joining region 18 paired with β-chain variable region 11 (Vα24-Jα18-Vβ11) in humans, and Vα14-Jα18 paired with Vβ8, Vβ7 or Vβ2 in mice). Nevertheless, despite this restricted TCR repertoire, NKT cell TCRs bind an array of different CD1d-restricted lipid-based antigens, including phospholipids9, as well as α-linked and β-linked glycolipids. The α-glycosidic linkage that defines α-galactosylceramide (α-GalCer) and other bacteria-derived NKT cell agonists, including α-glycuronosylceramides and α-galactosyldiacylglycerols, is considered to represent a 'microbial signature', as glycolipid antigens in mammals are typically β-linked anomers. The structures of NKT cell TCRs in complex with many α-linked glycolipids have been determined, including CD1d–α-GalCer and variants thereof and α-galactosyldiacylglycerol. Although the NKT cell TCR has been shown to be relatively rigid, conformational adjustments in complexes of CD1d and α-linked antigen permit optimal engagement of NKT cell TCRs. That is, a conserved docking topology is observed whereby the NKT cell TCR shows a parallel docking mode above the F′ pocket of the CD1d antigen-binding cleft, whereas the α-linked glycosyl moiety 'sits' snug and flat against CD1d, making many direct specificity-governing contacts with the NKT cell TCR.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-C50H99NO8S T cell receptor (Vα14Vβ8.2), pCDTCR1 (TCR-YC0255). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Other Products

TCR Vector Products

Autoimmune Disease related Products

Melanoma related Products

Breast Cancer related Products

Acute Lymphoblastic Leukemia (ALL) related Products

Prostate Cancer related Products

Pancreatic Cancer related Products

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout